Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.150
+0.020 (0.94%)
At close: May 1, 2026, 4:00 PM EDT
2.148
-0.002 (-0.11%)
After-hours: May 1, 2026, 7:59 PM EDT
Allogene Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
739.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALLO News
- 12 days ago - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewsWire
- 13 days ago - Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - GlobeNewsWire
- 17 days ago - Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - GlobeNewsWire
- 18 days ago - Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - GlobeNewsWire
- 18 days ago - Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - GlobeNewsWire
- 20 days ago - Allogene Therapeutics Transcript: Study result - Transcripts
- 20 days ago - Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Business Wire